
Ancient crop shows promise as sustainable jet fuel, University of Minnesota researchers say
Could this ancient crop fuel airplanes? U of M researchers think so
Could this ancient crop fuel airplanes? U of M researchers think so
Could this ancient crop fuel airplanes? U of M researchers think so
Every time we take flight, there's an environmental cost. Now, scientists are trying to grow a solution that could also be big business for Minnesota farmers.
At the University of Minnesota research fields, the sun shines on a solution in bloom.
"This is an ancient crop," said University of Minnesota researcher Matthew Ott
It's called Camelina.
"It's similar to canola, so it produces oil, but unlike canola, it survives a Minnesota winter," said Ott.
The seeds can be refined into cooking oil and further refined into sustainable aviation fuel.
"There have been flights using camelina fuel – soul camelina fuel," said Ott.
Ott is part of the team perfecting the crop for primetime. Something to stand up to Minnesota winters that farmers will flock to.
They're tiny seeds, but they could have a huge impact. The U.S. Department of Energy says sustainable aviation fuel could cut emissions by up to 94%.
And airlines want to cut emissions.
Globally, flying accounts for nearly 3% of our air emissions, but the industry wants to get to net-zero carbon emissions by 2050, with airlines like Delta aiming to use 10% sustainable fuel by 2030. Ott says it could be a big industry for the state.
"We're kind of the leader of developing it as a winter crop," said Ott.
Farmers across the state are piloting the product right now. Some tell us they use it as a cover crop and love that they can grow a second crop on the same land during the same season.
"Soybean can be planted directly in the camelina. They grow together just for a few weeks, and the camelina pods can be harvested over the top of the soybean seedlings," said Ott.
He says it also helps prevent runoff of farming fertilizers, improving water quality.
And the early bloomer provides nourishment for critical pollinators.
"It grows fast," said Ott.
Many are hoping the industry will, too.
"We're in the early in the process, but we're scaling up," said Ott.
Burning this type of fuel still produces emissions, but experts say it significantly cuts emissions when considering the whole life cycle of the product.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Epigenetics Diagnostics Market Analysis 2025-2034: Oncology Led with 68.7% Share in 2024, Driven by Demand for Early and Precise Cancer Detection Through Epigenetic Markers
The market, dominated by DNA methylation, sees significant contributions from North America, with the U.S. leading. Major players include Thermo Fisher Scientific, Illumina, and Roche Diagnostics, focusing on innovative tools that enhance precision medicine. Epigenetics Diagnostics Market Dublin, June 17, 2025 (GLOBE NEWSWIRE) -- The "Epigenetics Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to Global Epigenetics Diagnostics Market was valued at USD 15.5 billion in 2024 and is estimated to grow at a CAGR of 16.5% to reach USD 70.7 billion by 2034. The market is gaining momentum due to the rising awareness of how epigenetic mechanisms contribute to disease development, especially in complex and chronic conditions. The continuous evolution of diagnostic technologies is another key factor driving growth. Increasing cases of chronic illnesses and cancer globally have created a pressing demand for early and accurate detection methods. This, in turn, has fueled the need for advanced epigenetic biomarkers and testing assays. Additionally, the expanding use of next-generation sequencing technologies and AI-powered analytics has significantly improved the efficiency and scalability of epigenetic diagnostics. The growing preference for non-invasive procedures like liquid biopsies has further encouraged market adoption. Collaborations among pharmaceutical manufacturers, research bodies, and diagnostics firms are increasing to develop safer and more effective diagnostic tools. These initiatives are helping accelerate the transition of epigenetic diagnostics from research labs to mainstream clinical use. With heightened interest in precision medicine, the industry is seeing a sharp focus on the development of highly accurate and scalable solutions that support early intervention and personalized treatment market centers on technologies used to detect and analyze epigenetic markers, including DNA methylation and histone modifications, which are pivotal in identifying disease risks and progression. These diagnostics offer valuable insights for early-stage diagnosis and treatment planning across a range of conditions, including cancer and neurological disorders. Based on product type, the market is segmented into instruments, kits and reagents, and software and services. In 2024, the kits and reagents category led the market with a valuation of USD 7.6 billion. These products are integral to routine diagnostic workflows and are extensively used in clinical settings, academic research, and pharmaceutical development. Their ease of use, reliability, and compatibility with automated and high-throughput systems such as PCR and sequencing platforms make them widely preferred. Continuous improvements in assay sensitivity and integration with advanced technologies are driving further adoption. Additionally, the increasing emphasis on environmentally sustainable and cost-effective reagent development has enhanced accessibility, particularly in developing terms of application, the epigenetics diagnostics market is split between oncology and non-oncology diagnostics. The oncology diagnostics segment commanded a dominant share of 68.7% in 2024. This growth is propelled by the demand for early and precise cancer detection using epigenetic markers. DNA methylation and histone changes are commonly linked to various forms of cancer and serve as effective indicators for early diagnosis. The rising number of cancer cases, coupled with the shift toward personalized therapies, has heightened interest in epigenetic diagnostics. Awareness campaigns and initiatives promoting early detection and treatment are also playing a pivotal role in expanding this on technology, the market includes DNA methylation, histone methylation, microRNA modification, chromatin structure analysis, and other methods. DNA methylation dominated the landscape with a value of USD 6.3 billion in 2024 and is projected to reach USD 28.5 billion by 2034. This segment's strength lies in its capacity to identify disease-specific methylation markers, enabling earlier and more accurate diagnoses. Techniques like bisulfite sequencing, methylation-specific PCR, and array-based assays have advanced the precision of methylation studies, allowing for more effective disease monitoring. Integration of these methods with next-generation sequencing tools continues to improve test sensitivity and throughput, making them increasingly valuable in both research and clinical end user, the market is divided into hospitals and clinics, pharmaceutical and biotechnology companies, diagnostic laboratories, and others. Hospitals and clinics led the market in 2024 and are expected to reach USD 25.9 billion by 2034. These institutions play a vital role in deploying epigenetic testing for diagnostics, prognosis, and treatment monitoring. Their infrastructure and expertise allow for comprehensive testing and interpretation, including genetic counseling and interdisciplinary collaboration. The trend toward precision medicine has further boosted demand within hospitals, which often serve as central hubs for patient care and advanced North America held the largest share in 2024, accounting for 39.7% of the global market. The U.S. alone was valued at USD 5.4 billion in the same year. Factors contributing to the region's dominance include robust healthcare infrastructure, high investments in genomic research, and increased adoption of precision diagnostics. Government initiatives and funding support, especially from research bodies, have helped accelerate innovation in epigenetics. The growing burden of chronic diseases and a strong emphasis on non-invasive diagnostics continue to propel demand in the companies - Thermo Fisher Scientific, Illumina, QIAGEN, Agilent Technologies, and Roche Diagnostics - collectively held around 65% of the market share. These firms stay ahead through continuous innovations in sequencing systems, methylation detection tools, and integrated bioinformatics. Their expanding portfolios, including single-cell analysis and targeted panels, align with the rising demand for tailored diagnostic Market Analysis and Forecast Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape Competitive landscape with Porter's Five Forces and PESTEL analysis Market size, segmentation, and regional forecasts In-depth company profiles, business strategies, financial insights, and SWOT analysis Key Attributes Report Attribute Details No. of Pages 133 Forecast Period 2024-2034 Estimated Market Value (USD) in 2024 $15.5 Billion Forecasted Market Value (USD) by 2034 $70.7 Billion Compound Annual Growth Rate 16.5% Regions Covered Global Key Topics CoveredChapter 1 Methodology and Scope1.1 Market scope and definitions1.2 Research design1.2.1 Research approach1.2.2 Data collection methods1.3 Base estimates and calculations1.3.1 Base year calculation1.3.2 Key trends for market estimation1.4 Forecast model1.5 Primary research and validation1.5.1 Primary sources1.5.2 Data mining sourcesChapter 2 Executive Summary2.1 Industry 360 degree synopsisChapter 3 Industry Insights3.1 Industry ecosystem analysis3.2 Industry impact forces3.2.1 Growth drivers3.2.1.1 Increasing prevalence of cancer and chronic diseases3.2.1.2 Advancements in epigenomics research and technology3.2.1.3 Growing demand for non-invasive diagnostics3.2.2 Industry pitfalls and challenges3.2.2.1 High cost of epigenetic diagnostics technologies3.2.2.2 Limited standardization of testing methods3.3 Growth potential analysis3.4 Regulatory landscape3.5 Trump administration tariffs3.5.1 Impact on trade3.5.1.1 Trade volume disruptions3.5.1.2 Retaliatory measures3.5.2 Impact on the Industry3.5.2.1 Supply-side impact (raw materials)3.5.2.1.1 Price volatility in key materials3.5.2.1.2 Supply chain restructuring3.5.2.1.3 Production cost implications3.5.2.2 Demand-side impact (selling price)3.5.2.2.1 Price transmission to end markets3.5.2.2.2 Market share dynamics3.5.2.2.3 Consumer response patterns3.5.3 Key companies impacted3.5.4 Strategic industry responses3.5.4.1 Supply chain reconfiguration3.5.4.2 Pricing and product strategies3.5.4.3 Policy engagement3.5.5 Outlook and future considerations3.6 Technological landscape3.7 Future market trends3.8 Porter's analysis3.9 PESTEL analysisChapter 4 Competitive Landscape, 20244.1 Introduction4.2 Company market share analysis4.3 Company matrix analysis4.4 Competitive analysis of major market players4.5 Competitive positioning matrix4.6 Strategy dashboardChapter 5 Market Estimates and Forecast, by Product, 2021-2034 ($ Mn)5.1 Key trends5.2 Kits and reagents5.3 Instruments5.4 Software and servicesChapter 6 Market Estimates and Forecast, by Application, 2021-2034 ($ Mn)6.1 Key trends6.2 Oncology diagnostics6.3 Non-oncology diagnosticsChapter 7 Market Estimates and Forecast, by Technology, 2021-2034 ($ Mn)7.1 Key trends7.2 DNA methylation7.3 Histone methylation7.4 MicroRNA modification7.5 Chromatin structures7.6 Other technologiesChapter 8 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)8.1 Key trends8.2 Hospital and clinics8.3 Pharmaceutical and biotechnology companies8.4 Diagnostic laboratories8.5 Other end useChapter 9 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)9.1 Key trends9.2 North America9.2.1 U.S.9.2.2 Canada9.3 Europe9.3.1 Germany9.3.2 UK9.3.3 France9.3.4 Spain9.3.5 Italy9.3.6 Netherlands9.4 Asia-Pacific9.4.1 China9.4.2 Japan9.4.3 India9.4.4 Australia9.4.5 South Korea9.5 Latin America9.5.1 Brazil9.5.2 Mexico9.5.3 Argentina9.6 Middle East and Africa9.6.1 South Africa9.6.2 Saudi Arabia9.6.3 UAEChapter 10 Company Profiles10.1 Abcam10.2 Agilent Technologies10.3 Diagenode10.4 Dovetail Genomics10.5 Element Biosciences10.6 Illumina10.7 Merck10.8 New England Biolabs10.9 PacBio10.10 Promega10.11 QIAGEN10.12 Roche Diagnostics10.13 Thermo Fisher Scientific10.14 Zymo Research For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Epigenetics Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


CNN
an hour ago
- CNN
How AI Might Be Helping Your Doctor Treat You - Chasing Life with Dr. Sanjay Gupta - Podcast on CNN Audio
Dr. Sanjay Gupta 00:00:03 Welcome to Paging Dr. Gupta. You know, I really love these episodes in large part because they're all about you. Your questions, your concerns, your curiosity, about health and medicine, topics that are near and dear to my heart. Whether it's something in the headlines or something that's happening in your own life, share it and I'll try my best to try and help break it down. New week, new questions, Kyra is back. Who do we have first? Kyra Dahring 00:00:31 Okay, we're kicking things off today with a question from Kim. She's a nurse out in Los Angeles, and she's thinking ahead about how tech might change her day to day. Here's her question: Listener Kim 00:00:41 Hi, Dr. Gupta, my name is Kim and I'm a nurse. Um, with the incoming era of AI, what's in store for the medical community, whether that's medical procedure, a surgical procedure, diagnostics, or even as simple as making our notes on the patient's medical chart. Looking forward to hear what we have. Thank you so much. Dr. Sanjay Gupta 00:01:10 'Okay, Kim, thank you very much for this. This is a topic that I think about a lot. In full disclosure, I sit on the National Academy of Medicine, and there is a subcommittee on artificial intelligence that I sit on that as well, so I've been pretty immersed in the intersection of AI and healthcare for a while. And I'll tell you two things as top lines. One is that I'm bullish on it. It's here, it's definitely here to stay. And it's already being transformative. And two is that you have probably already been affected by AI in healthcare. If you've had any kind of recent visits to the doctor, to a hospital, to a clinic, your care was probably already impacted by AI in some way. Let me break down a few basics as I often do. You will hear about two main types of AI in health care: Predictive AI and Generative AI. Okay, so predictive AI is basically analyzing large sets of data, everything from age of patients, symptoms, test results, and that can help doctors make more informed decisions. It looks at lots and lots of data. Maybe it finds lots and lot of people who are just like the person they are investigating and they say, okay, here's the problem this person had. Here's the outcomes that we see in thousands, hundreds of thousands of people around the country around the world and that helps predict what we should do best. During colonoscopies AI can for example flag polyps that might otherwise be deemed inconsequential. With mammograms, the FDA has already cleared two dozen AI tools to help spot early signs of breast cancer, predicting breast cancer. In Stroke care AI models now pinpoint the timing of a stroke sometimes twice as accurately as humans, which is really crucial because that will determine in part if someone can receive certain life-saving or life-altering treatments. Hospitals are using AI to catch signs of sepsis before they become obvious. There are also tools a company say can now detect things like bone fractures that may go undetected by the patient, signs of over a thousand diseases that may exist even before symptoms show up. And then there is generative AI, and I think that's what people often think of when they think of the ChatGPT style stuff. It's mostly happening behind the scenes. One big use case for generative AI is documentation. So maybe you've heard of Microsoft's Dragon Copilot, so this is a platform that kind of listens in during a visit and then writes up the clinical note that is generated afterwards, helps draft letters that are sent to insurance companies to get medications or procedures approved. More advanced versions combine AI with real world medical data, that's called ChatRWD, and they are continuously being tested to reliably answer doctor's clinical questions. There's a platform that I use quite a bit and I think about a quarter of physicians in the country now use it called OpenEvidence, which again is looking at these large sets of data and then using that data in real time to answer questions. How long do we wait to start aspirin after a person has had a procedure, had an operation? These are tools that I'm already using. Now, I will tell you one thing that's interesting about these platforms is that there is very high expectations of how well they will work. You know, I think a lot of people think of AI platforms like they think of a computer. If you go to your computer and you ask your computer, you know, any question you might ask... You get an answer, you sort of expect that that answer is accurate. You don't then go to another computer and ask another computer to verify what the first computer said. But AI is a little bit different in this regard. In some ways, it's less like a computer and more like a tool that is trying to replicate human consciousness, which can falter, right? So there's a trust gap. There was this 2023 survey that found most Americans feel discomfort with doctors using AI to manage their care. So high expectations, low trust. There aren't many things in society like that. I would think, for example, autonomous vehicles might fall into that category. Even though there are car accidents all the time, it's one of the leading causes of preventable death in the United States, if an autonomous vehicle gets into an accident, it almost feels existential because the expectations are so much higher. So high expectations, low trust, when it comes to things like AI. AI can make mistakes. It can hallucinate, that's how it's often referred to, especially if the platform's been trained on incomplete data or biased data. Privacy is still an issue. I mean, HIPAA applies to AI platforms and healthcare, but I think that there's concerns about how might that information be stored or shared. So bottom line, Kim, AI is here. I'm bullish on it. I think it's already making an impact. It's already working in the background. It's improving diagnostics, documentation, access. But with many things in life, we often adopt a trust but verify model. And I think AI and healthcare should be treated the same way. Dr. Sanjay Gupta 00:06:48 Coming up, there are a lot of pain medications out there, but not all of them are right for every kind of pain. It's sometimes surprising what works best for what. I'll break it down after the break. Dr. Sanjay Gupta 00:07:03 Last week, I told you that I've been working on a book all about pain, it's called "It Doesn't Have to Hurt". It comes out September 2nd. It's something I've thinking about for a long time. Big part of writing a book like this is to try and give you some real takeaways when dealing with pain. And I thought I would start here, this podcast, Paging Dr. Gupta podcast, to share some of what I've learned. And I asked Kyra, in this case, just to give me the first question that came to her mind. Kyra Dahring 00:07:31 All right, Sanjay, well, you know what this sound means. I just had to do it, considering this is my first official page to Dr. Gupta. So my question, I'm asking this for myself and hopefully a lot of the people listening, you know, there are so many pain medications out there with all these different brand names and it's hard to know which ones are alike or when to take what. So my questions is, are they basically all the same and created equal? Or should we actually be picking different ones for different kinds of pain? Dr. Sanjay Gupta 00:08:00 'Okay, that is a good place to start, Kyra, thank you. First of all, let me just preface by saying, again, that 20% roughly of the country, one in five people suffers with chronic pain. It's an enormous number. I mean, when you have chronic pain, that is your whole life. You are defined by it. So they're thinking about pain all the time, they're suffering with pain all of the time. Their mood is different, they eat differently. Everything is different because of chronic pain so this is a big issue. But let's break down the different categories. The common ones, acetaminophen, Tylenol reduces fever very well. That is a analgesic pain medication that essentially works in the brain to reduce mild to moderate pain by increasing the body's pain threshold and also changing to some extent how the body senses pain. So it actually makes the threshold at which you experience pain higher and changes the way that you actually sense it. Then you have a very large category of what are called NSAIDs, non-steroidal anti-inflammatory drugs. That's ibuprofen, Advil, Motrin, Naprosyn, Aleve. They reduce fever and they also block something known as prostaglandins, which are compounds that cause pain and inflammation. So they work in a different part of the pain cascade. Aspirin is also considered an NSAID, reduces pain, reduces inflammation, also reduces blood clotting. That's why a lot of people will use that as a sort of mild blood thinner. You're gonna wanna avoid NSAIDs like aspirin and ibuprofen if you are already taking blood thinners, okay? Because if you have uncontrolled high blood pressure, if you've ulcers, if you're other bleeding risks, they may thin your blood even a little bit more, probably avoid the non-steroidals. And generally speaking, ibupropin's gonna be a safer choice than aspirin for those with bleeding risks. And then after that, just in the over the counter sort of categories, you have topical pain relievers. These are anesthetics that temporary relief pain at the skin surface. Think of things like Voltaren. Obviously don't use it on open wounds or sores, but a lot of the topical pain relievers are gonna have some component of lidocaine in them. If you've ever had an allergy to lidocain, probably want to avoid this. Now, when should you use each one? So headaches, that's one of the most common sources of pain. Any of these oral painkillers could work for that. Some people will have better luck with some of them other than others. As I mentioned earlier, when it comes to fevers, Tylenol is gonna be probably a better bet. One little pro tip, if you have a headache because you've had a little too much to drink the night before, too much alcohol, then Tylenols not a good option because alcohol and Tylenol both are pretty hard on the liver. So I would avoid Tylenol certainly after a hangover. Really if you can avoid most of those medications for hangover type pain better get hydrated and the pain will pass. Now if you're talking about pain that's caused by things like arthritis, non-steroidal anti-inflammatories is what you should use. They're also best by the way for sunburn. Acetaminophen best for people who. May have gastrointestinal issues because the non-steroidal anti-inflammatories are pretty hard on the stomach. Neuropathic pain or nerve pain. So that's the sort of lancinating pain that might go down your arms or your legs, sort of stabbing or even electric-like pain sometimes. Sometimes the topical pain relievers can help there. Then there are different medications for neuropathetic pain that may require prescription as well. And those types of medications typically change the way the nerve is conducting a signal. And sometimes it just disrupts the conduction of the signal. Sometimes it slows it. But there are different medications that are totally different class of drugs than Tylenol or non-steroidal anti-inflammatories that can help with that nerve sort of pain. You know, a lot of what I write about in the book is how to best choose these medications. But a lot what the book is about is creating strategies where you hopefully never need any of these medications. Obviously everyone's going to have some pain in their life, but you can have a lot less pain, a lot less intense pain, and a much shorter duration of pain, with some pretty simple strategies. And I hope that everyone can get a better understanding of that, how to control pain, how to understand it when my book comes out, September 2nd, "It Doesn't Have To Hurt". Dr. Sanjay Gupta 00:12:43 'Big thanks to everyone who sent in the questions, Kyra, thank you. We're still building the show. We're doing it together and I'm glad you're part of it. If there's something health-related you've been curious about, don't be shy, share it, record a voice memo, email it to AskSanjay@ or give us a call at 470-396-0832 and leave a message. Thanks for listening, I'll be back next Tuesday. Chasing Life is a production of CNN Audio. Our podcast is produced by Eryn Mathewson, Jennifer Lai, Grace Walker, Lori Galaretta, Jesse Remedios, Sofia Sanchez, Kyra Dahring, and Madeleine Thompson. Andrea Kane is our medical writer, our senior producer is Dan Bloom, Amanda Sealy is our showrunner, Dan Dzula is our technical director, and the executive producer of CNN Audio is Steve Lickteig. With support from JJamus Andrest, Jon Dianora, Haley Thomas, Alex Manasseri, Robert Mathers, Leni Steinhardt, Nichole Pesaru, and Lisa Namerow. Special thanks to Ben Tinker and Nadia Kounang of CNN Health and Wendy Brundige.
Yahoo
an hour ago
- Yahoo
Corvia Medical closes $55 million funding round to complete confirmatory trial and pursue FDA approval of Corvia Atrial Shunt
Existing investors provide funding to finish international RESPONDER-HF trial TEWKSBURY, Mass., June 17, 2025 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the successful closure of a $55 million funding round from the company's existing investment syndicate of Third Rock Ventures, General Catalyst Partners, AccelMed, Lumira Ventures, and two strategic investors. The funds will be used to complete the ongoing RESPONDER-HF trial, a double-blinded, randomized, sham-controlled, confirmatory trial of the Corvia® Atrial Shunt currently underway at more than 65 institutions on three continents. The study is expected to generate the final supportive clinical data required for FDA approval of the shunt as a breakthrough treatment for heart failure with preserved and mildly reduced ejection fraction (HFpEF/HFmrEF). "We are profoundly grateful for the unwavering support of our longstanding investors as we advance toward FDA submission of the Corvia Atrial Shunt," said George Fazio, CEO of Corvia Medical. "Their commitment furthers our mission to bring this transformative heart failure treatment to millions of patients worldwide." Paul LaViolette, Board Chair of Corvia Medical, added, "We firmly believe Corvia has the potential to fundamentally alter the landscape of heart failure treatment, and our investors share that vision. With these resources, we are well-equipped to drive the company through the approval process and introduce this groundbreaking therapy to the market." About heart failure (HF) and the Corvia Atrial Shunt More than 26 million people worldwide have HF, and the majority have HFpEF, making it the largest unmet clinical need in cardiovascular medicine. The Corvia Atrial Shunt is designed to reduce elevated left atrial pressure (LAP), the primary contributor to HF symptoms, by creating a passage between the left and right atria, reducing HF events and improving quality of life. The Corvia Atrial Shunt was granted Breakthrough Device designation by the FDA in 2019. For information regarding RESPONDER-HF study eligibility, please visit About Corvia Medical, Inc. Corvia Medical, Inc. is revolutionizing the treatment of heart failure through novel transcatheter cardiovascular devices. Founded in 2009 and headquartered in Tewksbury, MA, privately-held Corvia is dedicated to transforming the standard of care for heart failure treatment, enabling patients to reclaim their lives. Visit MEDIA CONTACT:Lisa Ensz+1 978-654-6120lensz@ View original content: SOURCE Corvia Medical, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data